modelRiluzole
Extends from Pharmacolibrary.Drugs.ATC.N.N07XX02.
Information
| name: | Riluzole | |
| ATC code: | N07XX02 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 245 | L |
| clearance: | 376 | mL/min |
| other parameters in model implementation | ||
Riluzole is an oral glutamate release inhibitor used primarily for the treatment of amyotrophic lateral sclerosis (ALS). It slows disease progression and prolongs survival in ALS patients. Riluzole is approved for clinical use in multiple countries including the US and EU.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult volunteers after single oral dosing.
References
Brooks, BR, et al., & Cazzaniga, S (2019). Riluzole Oral Suspension: Bioavailability Following Percutaneous Gastrostomy Tube-modeled Administration Versus Direct Oral Administration. Clinical therapeutics 41(12) 2490–2499. DOI:10.1016/j.clinthera.2019.09.016 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31635890
Sarkar, M, et al., & Chow, DS (2018). Rational design and development of a stable liquid formulation of riluzole and its pharmacokinetic evaluation after oral and IV administrations in rats. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 125 1–10. DOI:10.1016/j.ejps.2018.09.004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30201516
Bireley, JD, & Morren, JA (2023). CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS). Expert opinion on investigational drugs 32(8) 677–683. DOI:10.1080/13543784.2023.2252738 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37642362
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)